by Admin | July 21, 2010 8:53 pm
July 21, 2010 – 340B covered entities are now paying 9.44 percent less on average for prescription drugs than they were in April and May due to changes in the calculation of 340B ceiling prices that took immediate effect with the enactment of health care reform in late March.
Christopher Hatwig, vice president of Apexus/340B Prime Vendor Program (PVP), announced the preliminary figures during the 340B Coalition annual conference in Washington. He and other speakers, however, cautioned that the data are very raw and strongly advised against their use in making budgetary or any other sort of financial decisions.
The Affordable Care Act (ACA) changed the two factors that are used to determine 340B prices: the Medicaid unit rebate amount (URA) and average manufacturer price (AMP). The URA changes became effective retroactively to Jan. 1 but the AMP changes do not take effect until Oct. 1.
The fluctuations now being detected in 340B prices reflect the alterations to URA only. Hatwig and other conference speakers warned that it is still premature to say what will happen to 340B prices when the AMP changes kick in this fall.
From the end of the second quarter of 2010 to the early days of the third, 340B prices for brand-name drugs declined by an average of 10.43 percent. Generic drugs prices fell by 3.28 percent, oral drugs by 12.53 percent, and injectables by 7.86 percent.
Source URL: https://340binformed.org/2010/07/preliminary-data-show-9-4-decline-in-340b-prices/
Copyright ©2026 340binformed.org unless otherwise noted.